A putative GDP-Man PP (guanidine diphosphomannose pyrophosphorylase) gene from Trypanosoma brucei (TbGDP-Man PP) was identified in the genome and subsequently cloned, sequenced and recombinantly expressed, and shown to be a catalytically active dimer. Kinetic analysis revealed a V max of 0.34 μmol/min per mg of protein and K m values of 67 μM and 12 μM for GTP and mannose 1-phosphate respectively. Further kinetic studies showed GDP-Man was a potent product feedback inhibitor. RNAi (RNA interference) of the cytosolic TbGDP-Man PP showed that mRNA levels were reduced to ∼ 20 % of wildtype levels, causing the cells to die after 3-4 days, demonstrating that TbGDP-Man PP is essential in the bloodstream form of T. brucei and thus a potential drug target. The RNAi-induced parasites have a greatly reduced capability to form GDP-Man, leading ultimately to a reduction in their ability to synthesize their essential GPI (glycosylphosphatidylinositol) anchors. The RNAiinduced parasites also showed aberrant N-glycosylation of their major cell-surface glycoprotein, variant surface glycoprotein, with loss of the high-mannose Man 9 GlcNAc 2 N-glycosylation at Asn 428 and formation of complex N-glycans at Asn 263 .
INTRODUCTION
Eukaryotic glycosylation contains numerous examples of mannose-containing glycoconjugates, i.e. protein N-and Cglycans, some O-glycans and GPI (glycosylphosphatidylinositol) anchors, as well as some glycolipid membrane anchors, and all are known to have a variety of important/essential functions [1, 2] .
GDP-Man (guanidine diphosphomannose) is the critical metabolite for all mannose-glycoconjugate synthesis and is utilized directly or indirectly [via Dol-P-Man (dolichol-phosphatemannose) formation] as the mannose donor for all mannosylation reactions. GDP-Man PP (GDP-Man pyrophosphorylase, EC 2.7.7.13) catalyses GDP-Man formation from mannose 1-phosphate and GTP, forming the by-product pyrophosphate.
The most common form of glycosylation in eukaryotes is N-glycosylation, which utilizes both GDP-Man and Dol-PMan, formed by Dol-P-Man synthase using GDP-Man and Dol-P. Formation of the lipid-linked oligosaccharide precursor (Man 9 GlcNAc 2 -PP-Dol), takes place in the ER (endoplasmic reticulum), where the first five mannoses are added to GlcNAc 2 -PP-Dol by GDP-Man-dependent mannosyltransferases on the cytoplasmic face. Following flipping of the Man 5 GlcNAc 2 -PPDol intermediate, the last four mannoses are added by Dol-PMan-mediated mannosyltransferases on the luminal side of the ER. The glycan portion is then transferred en bloc to asparagine residues within an Asn-Xaa-Ser/Thr sequon of a growing nascent protein [3] .
Protein N-glycosylation of many membrane and secretory glycoproteins in eukaryotes serve a wide variety of functions, including the promotion of correct folding, solubility, protein stabilization, endocytic sorting functions, protease resistance and signalling through interaction with lectins [3] [4] [5] . In Saccharomyces [6] and Candida [7] , covalent linkage formation between cell-wall proteins and glucans is mediated in part by GDP-Man PP [8] . In mycobacteria, GDP-Man PP is used to elongate the oligosaccharides of lipoglycans, lipomannan and lipoarabinomannan, potent immunomodulators in tuberculosis and leprosy [9] . Other examples of the broad biological role played by GDP-Man include being a key intermediate in the biosynthetic pathway of ascorbic acid (vitamin C) in plants [10, 11] , and the precursor for GDP-fucose synthesis [12, 13] , used to fucosylate eukaryotic glycoconjugates, involved in tissue development, angiogenesis, fertilization, cell adhesion, inflammation and tumour metastasis.
In eukaryotic human pathogens, such as Leishmania, which produce large amounts of unusual mannose-rich cellsurface-associated and secreted glycoconjugates, N-glycans, GPI anchors, O-phosphoglycosylated proteophosphoglycans, lipophosphoglycan and glycoinositolphospholipids, the GDPMan PP gene is a virulence factor in Leishmania mexicana, since its deletion causes a loss of the capability to infect macrophages and mice [14, 15] .
The closely related protozoan pathogen Trypanosoma brucei, the causative agent of African sleeping sickness, also expresses an essential glycosylated cell-surface molecule heavily dependent upon GDP-Man for its biosynthesis. Approx. 5×10 6 dimers of the VSG (variant surface glycoprotein) are attached to the plasma membrane by a GPI anchor. This dense coat protects the parasite from components of the host complement system and, through antigenic variation, from specific immune responses [16 -18] .
Despite the variation of the VSG protein, the GPI core structure attached to protein remains unchanged and comprises NH 2 CH 2 CH 2 PO 4 H-6Manα1-2Manα1-6Manα1-4GlcNα1-6D-myo-inositol-1-HPO 4 -dimyristylglycerol [19] . Three distinct Dol-P-Man-dependent mannosyltransferases are used in the biosynthesis of GPI anchors. The GPI biosynthetic pathway has been both genetically and chemically validated as a potential therapeutic drug target in bloodstream-form T. brucei [20 -22] .
All variants of VSG are also modified with between one and three N-glycans [23] . VSG variant 221 (MiTat1.2) expressed by the cell-line used in the present study, has two Nglycosylation sites: Asn 428 mostly occupied by oligomannose structures, i.e. Man 5−9 GlcNAc 2 , whereas the Asn 263 site is occupied by biantennary structures, i.e. Man 3−4 GlcNAc 2 and GalGlcNAcMan 3 GlcNAc 2 [24] . Seminal work by the Ferguson group [25, 26] has shown that T. brucei is unusual among eukaryotes, as they are able to transfer en bloc [presumably by the different putative homologues of oligosaccharyltransferase STT3 subunits identified in the genome (Tb 927.5.890, Tb 927.5.900, Tb 927.5.910)], in a site-specific manner, Man 9 GlcNAc 2 -PP-Dol for Asn 428 and Man 5 GlcNAc 2 -PP-Dol for Asn 263 of VSG221. In fact a recent paper has demonstrated that in a yeast ex vivo system, T. brucei oligosaccharyltransferase subunits are specific for transferring either biantennary or triantennary structures [47] .
In the present study we characterize the recombinant TbGDPMan PP (T. brucei GDP-Man PP) and assess the effects of having limiting amounts of GDP-Man, induced by a TbGDP-Man PP RNAi (RNA interference) cell-line on the formation of mature (N-glycosylated and GPI-anchored) VSG.
EXPERIMENTAL

Cloning of the TbGDP-Man PP gene and formation of constructs
A putative GDP-Man PP gene was identified in the T. brucei genome database (http://www.genedb.org) [40] , using a tBlastN search with the Saccharomyces cerevisiae GDP-Man PP genomic sequence as the query. The ORF (open reading frame) was amplified from T. brucei gDNA (genomic DNA) using the forward and reverse primers 5 -GCAGCCATATGAGGGC-CGTCATTCTTGTTGGAGG-3 and 5 -CCGCTCGAGCAT-GACCACTTCTGGTTCGGGGTGATTT-3 containing Nde1 and Xho1 restriction sites respectively (underlined). A band of the expected size of approx. 1.1 kb was amplified using Pfu polymerase, purified using a QIAquick PCR purification kit (Qiagen), cloned into pCR-Blunt II TOPO (Invitrogen) and the sequence confirmed.
The last ∼ 300 bp of the TbGDP-Man PP ORF was excised using BamHI and XhoI and ligated into the tetracycline-inducible RNAi vector p2TZ [41] . The sequence was confirmed and plasmid DNA was prepared using a QIAprep Miniprep Plasmid Kit (Qiagen). After digestion with NotI, it was precipitated with sodium acetate/ethanol and dissolved in sterile water to a final concentration of 1 μg/μl ready for transformation. The GDP-Man PP ORF was excised from the TbGDP-Man PP-TOPO plasmid using Nde1 and Xho1 restriction sites. The product was purified using a QIAquick Gel purification kit (Qiagen) and ligated into pET20b (Novagen) vector, and the sequence confirmed.
Determination of native molecular mass by gel-filtration
Gel-filtration analysis was performed using a high-resolution Sephacryl S-300 column (1.6 cm diameter, 60 cm long, bed volume of 120 ml), which was equilibrated in 20 mM Hepes, 150 mM NaCl and 8 mM MgCl 2 (pH 7.0), and run at 0.5 ml/min. The column was calibrated with globular protein standards (BioRad Laboratories).
Expression and purification of recombinant TbGDP-Man PP
The TbGDP-Man PP pET20b construct was transformed into BL21 competent Escherichia coli cells for expression. A single colony of freshly transformed cells was used to inoculate 200-500 ml of the auto-inducing medium ZYP-5052 [42] , containing 100 μg/ml ampicillin and grown at 15
• C for 24-48 h, after which the cells were harvested by centrifugation (800 g for 10 min) and stored at −20
• C. Frozen pellets were suspended in lysis buffer [20 mM Tris/HCl (pH 7.9), 300 mM NaCl and 5 mM imidazole] and incubated on ice with 0.2 mg/ml lysozyme (Sigma) for 30 min. Cells were disrupted by sonication (3×30 s) on ice and the supernatant was cleared by centrifugation (14 000 g for 15 min at 4
• C). Soluble GDP-Man PP was purified by batch absorption to nickel-agarose (Qiagen). Briefly, the clarified supernatant was mixed with approx. 50 μl/ml nickel-agarose (pre-equilibrated in lysis buffer) and incubated for 1 h at 4
• C with gentle mixing. The slurry and supernatant were decanted into a Poly-Prep chromatography column (0.8 cm×4 cm; BioRad Laboratories) and the packed resin was washed with lysis buffer containing 60 mM imidazole until no protein could be detected in the outflow (approx. 5 column volumes). The bound GDP-Man PP was eluted with 1-2 ml of lysis buffer containing 1 M imidazole and was buffer-exchanged into 50 mM Hepes and 8 mM MgCl 2 (pH 7.0) by three cycles of concentration and dilution through a Vivaspin 6 spin column with a molecular mass cut-off of 10 kDa (Sartorius). The sample was adjusted to 20 % glycerol and stored at −20
• C. The purity of the recombinant GDP-Man PP was assessed by SDS/PAGE and LCT ESI-MS (electrospray ionization mass spectrometry) (Centre for Biomolecular Science, St Andrews University, St Andrews, Scotland, U.K.). Protein concentration was determined using the Bio-Rad protein assay kit using BSA as the standard.
Assay of GDP-Man PP activity
A 96-well plate assay was established for GDP-Man PP activity, based on an assay described by Davis et al. [32] . Briefly, the standard assay reaction consisted of, in a final volume of 50 μl, 50 mM Hepes (pH 7.0), 8 mM MgCl 2 , 125 μM GTP, 125 μM mannose 1-phosphate, 1 mM DTT (dithiothreitol), 0.1 unit/ml pyrophosphorylase and 0.1-0.5 μg of GDP-Man PP. The reaction was initiated by addition of enzyme or substrate and allowed to proceed for 30 min at 30
• C. The reaction was terminated by the addition of 100 μl of the detection reagent Biomol Green (Biomol Research Laboratories) and the absorbance was read at 620 nm after a further 20 min incubation at room temperature (18 • C). The amount of pyrophosphate produced was estimated from a standard curve of 0-20 μM sodium pyrophosphate made up in the standard assay mix.
For each assay, a substrate blank and enzyme blank were carried out to account for any free phosphates already present in the sample and any non-specific activity of GDP-Man PP. Specific activity is defined as units/mg of protein, where 1 unit is the amount of pyrophosphate (μM) released per min at 30
• C.
HPLC analysis of the GDP-Man PP reaction
The soluble reactants and products from a reaction of GTP and mannose 1-phosphate in the absence or presence of TbGDP-ManPP were separated on a Hypersil SAX 5μ HPLC column (4.6 mm×250 mm; Alltech), using a general method to separate nucleotides and nucleotide-phosphate sugars as described previously [43] .
Southern blot analysis
The GDP-Man PP ORF was PCR-amplified using the same primers as described above and gel-purified with a QIAquick gel extraction kit (Qiagen). This fragment was then labelled with fluorescein (Gene ImagesRandom prime module; Amersham Biosciences) and used for Southern blot analysis of T. brucei gDNA as described previously [44] .
Cultivation and genetic modification of T. brucei
Bloodstream-form T. brucei strain 427, which had been previously modified to express both T7 polymerase and the tetracycline repressor protein [45] , are referred to in the present paper as wildtype cells for convenience. Cells were grown in HMI-9 medium supplemented with G418 (2.5 μg/ml) at 37
• C with 5 % CO 2 as described previously [21, 45] . Transformation conditions and subsequent drug selection have also been described elsewhere [21, 45] . For tetracycline (a final concentration of 1 μg/ml)-induced RNAi experiments, cells were resuspended in the same HMI-9 medium at 5×10 4 cells/ml. Cells were counted each day and were passaged only when the density was between 2×10 6 and 3×10 6 (normally every second day).
RNA isolation and cDNA synthesis
Total RNA was isolated from bloodstream-form T. brucei using the RNeasy mini kit (Qiagen). TbGDP-Man PP-specific cDNA was generated and amplified using the specific forward 5 -GCAGCCATATGAGGGCCGTCATTCTTGTTGGAGG-3 and reverse 5 -CCGCTCGAGTTACATGACCACTTCTGGTTCG-GGGTGATTT-3 primers using the SuperScript III One step RT (reverse transcription)-PCR kit with Platinum Taq (Invitrogen). As a negative control to exclude DNA contamination of the RNA sample, reverse transcriptase was omitted from the reaction and replaced with GoTaq polymerase (Promega). Inositol-3-phosphate synthase (TbINO1) cDNA was also amplified using the forward and reverse primers 5 -AGC-GGCAAGCTTCTATGCCAGCCGTCCGTACGAAAA-3 and 5 -CGACCTCGAGGTCAACTTCCCACGCCGCGAAGGAAA-GGCAG-3 to show equal RNA input. The PCR products were then run on a 1 % agarose gel.
Subcellular localization studies
Mid-exponential phase bloodstream-form cells were harvested by centrifugation (800 g for 10 min) and used for either immunofluorescence or differential centrifugation. For immunofluorescence, the cells were fixed with 4 % paraformaldehyde (4 • C, overnight). An aliquot of the fixed cells were processed as described previously [46] , before incubation with the primary antibody, recombinant L. mexicana GDPMan PP anti-rabbit antibody (a gift from Dr E. Handman, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia), and the secondary FITC-conjugated rabbit anti-rat immunoglobulins (DakoCytomation).
For differential centrifugation, cellular fractions were prepared as described previously [46] . Proteins were separated by SDS/PAGE and transferred on to an ECL (enhanced chemiluminesence)-nylon membrane by Western blotting. After blocking overnight in PBS/5 % skimmed milk powder, protein was detected using the primary antibody, recombinant L. mexicana GDP-Man PP anti-rabbit antibody, and secondary antibody, HRP (horseradish peroxidase)-conjugated rabbit antirat immunoglobulins (Jackson) and ECL Western blot detection reagents.
In vivo T. brucei metabolic labelling
For each metabolic labelling, 2×10 7 mid-exponential phase cells were centrifuged (800 g for 10 min), washed in glucosefree minimal essential medium, before being resuspended in the same medium at a final concentration of 1×10 7 cells/ml. Cells were labelled for 1 h (pulse) or 2 h (pulse-chase) at 37
3 H]myristate (30 Ci/mmol; ARC), in a shaking water bath. For pulse-chase experiments, after 1 h of labelling an equal volume of normal medium (HMI-9) was added and the labelling allowed to continue for a further 1 h. The cells were collected by centrifugation (800 g for 10 min) and samples taken for either lipid or protein analysis. Lipids were extracted using chloroform/methanol/water (10:10:3, by vol.) for 1 h, the supernatant was removed and the pellet reextracted with chloroform/methanol (2:1, v/v) for 1 h. The supernatants were pooled and dried before samples were desalted using butanol/water partioning. Lipids were separated by HPTLC (high-performance TLC) using silica 60 HPTLC plates and chloroform/methanol/water (10:10:3, by vol.) as the solvent. • C. To quench the labelling, the cells were diluted in 20 ml of ice-cold TDB [trypanosome dilution buffer; 5 mM KCl, 80 mM NaCl, 1 mM MgSO 4 , 20 mM Na 2 HPO 4 , 2 mM NaH 2 PO 4 and 20 mM glucose (pH 7.7)] containing 1 mM L-methionine and centrifuged (800 g for 10 min at 4
• C). After the supernatant was removed, the cells were resuspended in TDB and an equal volume of 2×SDS/PAGE sample buffer was added prior to heating at 100
• C for 5 min. Proteins were separated on SDS/PAGE (10 % gels) and visualized by Coomassie Blue staining. To detect 35 S-labelled proteins, the destained gel was soaked in En 3 hance TM (NEN) for 30 min, washed twice with water, soaked in 10 % glycerol and dried. The dried gel was then exposed to XAR-5 film overnight at −70
Isolation and enzymatic digests of sVSG (soluble-form VSG)
Small-scale sVSG purification and subsequent digests with either Endo H (endoglycosidase H) or PNGase F (peptide N-glycosidase F; Calbiochem) were performed as described previously [25] .
ESI-MS analysis of sVSG
sVSG obtained and purified as described above, ∼0.1 μg/μl sVSG in 50 % acetonitrile and 1 % formic acid, was loaded into nanotips (Micromass-type F). Positive-ion electrospray mass spectra on an ABI QSTAR-XL system with a tip potential of ∼ 2000 V and declustering potential of 60 V were recorded. Deconvolved data were formed using ABI Analyst software in conjunction with the Bayesian protein reconstruct program.
ESI-MS and ESI-MS/MS (ESI-tandem MS) analysis of glycopeptides obtained by pronase treatment of sVSG
Aliquots of sVSG (approx. 50 μg in 150 μl of water) were mixed with 15 μl of 1 M ammonium bicarbonate and 30 μl of 1 mg/ml pronase in 5 mM calcium acetate, and incubated at 37
• C for 36 h. The pronase glycopeptides were purified/enriched using Envicarb graphitized carbon (Supelco) suspended in methanol and a bed of approx. 100 μl of graphitized carbon was packed into a spin column (Ambion). The columns were washed with 10 vol. of each of the following: 80 % methanol and 1 % formic acid, 60 % methanol and 1 % formic acid, and finally 1 % methanol and 1 % formic acid. The pronase digest (150 μl) was mixed with 850 μl of 1% methanol and 1 % formic acid and applied to the column five times. The column was washed ten times with 100 μl of 1% methanol and 1 % formic acid. Glycopeptides were eluted with 100 μl of 60% methanol and 1 % formic acid passed through the column ten times and concentrated. Aliquots of these samples were loaded into nanotips (Micromass-type F) and analysed by ESI-MS in positive-ion mode on an ABI Q-Star-XL instrument with tip and declustering potentials of 900 V and 60 V respectively. The product ion spectra of doubly charged species (81 m/z) were collected using collision energies of ∼ 40 V.
Quantification of intracellular GTP and GDP-hexose
The method for the quantification of NTPs and NDP-sugars is an adaptation of the method of Turnock and Ferguson [35] , and will be published in full elsewhere (L. Major, S. Fyffe and T.K. Smith, unpublished work). Briefly, a known number of cells were centrifuged at 800 g for 10 min at room temperature and washed in TDB. The cell pellet was lysed with 100 μl of icecold 1 M TCA (trichloroacetic acid) and 150 pmol of internal standard (2-deoxyinosine 5 -triphosphate) was added to the lysate and centrifuged at 15000 g for 10 min at 4
• C. The supernatant containing the soluble metabolites was transferred to a fresh tube prior to 25 μl of 10 mM EDTA (pH 7.0) being added, followed by 50 μl of chloroform and 50 μl of trioctylamine. The mixture was vortex-mixed and centrifuged at 15000 g for 10 min at 4
• C. The upper phase was carefully transferred to a fresh tube, flash frozen and freeze-dried. The sample was resuspended in 60 μl of 50 % methanol and introduced to the mass spectrometer (Quattro Ultima Triple Quadrupole; Waters) by constant infusion at a rate of 30 μl/min. A MRM (multiple reactant monitoring) program was created, which specifically focused upon a set of mass transitions. The parent ion masses of GTP, GDP-hexose and the internal standard 2-deoxyinosine 5 -triphosphate were selected, and the number of ions of the principal daughter ion of each was recorded and normalized using the internal standard and standard curves.
RESULTS AND DISCUSSION
Cloning and sequencing TbGDP-Man PP
A putative GDP-Man PP was identified in the T. brucei genome database (Tb927.8.2050). The putative ORF was PCR-amplified from Lister 427 gDNA, cloned and sequenced. The sequence has been submitted to GenBank ® (accession number FM992872). An alignment of the predicted translated sequence with GDP-Man PP from other organisms is shown in Supplementary Figure S1 (at http://www.BiochemJ.org/bj/425/bj4250603add.htm).
TbGDP-Man PP shows considerable similarity to GDP-Man PP from a variety of organisms, unsurprisingly being most closely related to those from other kinetoplastids: Trypanosoma cruzi and Leishmania braziliensis. Comparative sequence analysis suggests that, like other GDP-Man PPs, the TbGDP-Man PP consists of two domains: an N-terminal nucleoside phosphate transferase domain (residues 2-235), which is highly conserved in a wide-range of NTP-utilizing enzymes. In addition, a C-terminal left-handed β-helix domain which contains several hexapeptide repeats (residues 268-349), which is common to a number of GDP-Man PP-related enzymes and has been implicated in mediating intramolecular associations, i.e. dimer or trimer formation [27] [28] [29] [30] . The sequence shows no evidence of the phosphomannose isomerase motif, which is a feature of some bi-functional GDP-Man PPs found in bacteria [31] .
Overexpression of GDP-Man PP in E. coli
To enable biochemical characterization, the TbGDP-Man PP was overexpressed in BL21 E. coli using a pET 20b vector, which encodes a C-terminal His 6 tag. The His-tagged recombinant TbGDP-Man PP protein was purified using Ni 2+ beads and subsequently eluted using increasing concentrations of imidazole ( Figure 1A ). The resultant protein was >95 % pure as assessed by SDS/PAGE (Figure 2A , lane 6) and ran with an apparent molecular mass of ∼ 42 kDa. The molecular mass of the purified recombinant protein was shown to be 41769.10 Da by LCT ESI-MS analysis, with a theoretical mass of 41769.32 Da.
The TbGDP-Man PP protein was purified further by gelfiltration ( Figure 1B) . Elution from the gel-filtration column showed that TbGDP-Man PP (arrow) exists predominantly as a dimer in solution when compared with molecular mass standards (see arrow in Figure 1C ). This is distinct from the L. mexicana GDP-Man PP which has been reported to be a hexamer (a dimer of trimers) in solution [32] , similar to GDP-Man PP from Salmonella enterica which is a homodimer [33] . Two structural homologues of GDP-Man PP, Glmu from Streptococcus pneumoniae and Rm1A from Pseudomonas aeruginosa, have been shown to form trimers and tetramers respectively [29, 30] . Typical yields obtained were 2-4 mg of protein per litre of bacterial culture, and TbGDPMan PP was found to be relatively stable when stored at −20
• C with 20 % glycerol.
Activity of TbGDP-Man PP
The purified TbGDP-Man PP recombinant protein was shown to be catalytically active by HPLC analysis (Figures 2A and  2B ). This showed the conversion of GTP into the product GDPmannose.
Catalytic activity of GDP-Man PP was measured through the use of a coupled assay, whereby the by-product of GDPMan PP activity, pyrophosphate, was used as a substrate for a pyrophosphatase, and the released phosphate was measured colorimetrically (Figure 2A) . This is quantitative, with the amount of phosphate released being directly proportional to the amount of GDP-Man and pyrophosphate produced by GDPMan PP, allowing subsequent kinetic analysis of the recombinant enzyme. Numerous controls were included to ensure that the pyrophosphatase activity was not limiting under any of the conditions used, and that no erroneous results were observed as a result of free phosphate being present in the assay prior to incubation with the pyrophosphatase. The enzyme had negligible ability to cleave phosphate from mannose 1-phosphate, GTP or other potential substrate/inhibitor (results not shown).
As with other GDP-Man PP proteins, the recombinant TbGDPMan PP activity has a neutral pH optimum (Supplementary Figure  S2A at http://www.BiochemJ.org/bj/425/bj4250603add.htm), all subsequent assays were carried out at pH 7.0. The reducing agent DTT had a slight stimulatory effect on the enzyme and was routinely included in the assay mixture at a concentration of 1 mM (Supplementary Figure S2B) . The enzyme also had an absolute requirement for divalent cations, with the maximium activity obtained in the presence of Mg 2+ (8 mM); however, this could be partially be replaced by Mn 2+ and Cu 2+ at certain concentrations (Supplementary Figure S2C) .
Kinetic parameters of TbGDP-Man PP were studied, all components of the standard assay were held constant and the GTP and mannose 1-phosphate concentrations varied between 0 and 0.625 mM. The enzyme presented simple hyperbolic kinetics with respect to both substrates with a V max of 0.34 + − 0.01 μmol/min per mg of protein, with K m values for GTP and mannose 1-phosphate being 67 + − 4 μM and 12 + − 1 μM respectively ( Figure 2C) . These values are similar to the kinetic parameters reported for other GDP-Man PPs [33, 34] . The K m of GTP is well within the observed intracellular concentration of 72 μM (L. Major, S. Fyffe and T. K. Smith, unpublished work), implying that the GDP-Man PP is working well below its V max .
Substrate/inhibitor specificity
To investigate the substrate specificity of the TbGDP-Man PP, a number of alternative nucleotide triphosphates and sugar 1-phosphate analogues up to a concentration of 1 mM were assessed initially as potential substrates and then as potential inhibitors (Table 1) . Only ATP showed appreciable activity as an alternative acceptor substrate, with hyperbolic kinetics giving a K m ∼ 290 μM ( Figure 3A) . Further kinetic analysis indicated that GDP-mannose was a competitive inhibitor with respect to GTP [K i ∼ 1.25 μM (Figures 4C and 4D) ], but exhibited mixedtype inhibition with respect to mannose 1-phosphate (K i ∼ 2 μM; results not shown). This suggests that the binding interaction of GDP-Man as an inhibitor is associated primarily with the GTP-binding site. The observed feedback inhibition obviously accounts for the surprisingly low steady-state intracellular GDPMan concentration in T. brucei [35] , despite it being in very high demand for N-glycosylation and GPI anchor biosynthesis. Other GDP-Man analogues were tested as potential inhibitors, only GDP-6-deoxymannose showed any significant inhibition with an IC 50 of ∼ 13 μM (Table 1 and Figure 3B ). 
GDP-Man PP is a cytosolic protein in bloodstream-form T. brucei
The localization of TbGDP-Man PP was investigated in the bloodstream form of the parasite. Wild-type T. brucei cells were fixed, allowed to adhere to poly-lysine slides and permeablized. The GDP-Man PP protein was detected by immunofluorescence using a primary antibody against the recombinant L. mexicana GDP-Man PP [39] , with a secondary TRITC (tetramethylrhodamine β-isothiocyanate)-conjugated anti-mouse antibody, followed by counter-staining with DAPI (4 ,6-diamidino-2-phenylindole). An even TRITC signal was observed through out the cell body, excluding the flagella, nucleus and kinetoplast (Supplementary Figures S4A-S4C at http://www.BiochemJ.org/bj/425/bj4250603add.htm), suggesting that TbGDP-Man PP is cytoplasmic. This result was supported by subcellular fractionation experiments followed by Western blot analysis (Supplementary Figure S4D) . The anti-L. mexicana GDP-Man PP antibody cross-reacts with the recombinant This cellular location is unsurprising, as the protein contains no transmembrane domains or signal sequences for specific cellular organelles predicted from the deduced amino acid sequence. Secondly, to date all GDP-Man PP proteins isolated from tissues of various eukaryotic and prokaryotic sources have been shown to be cytosolic.
GDP-Man PP is an essential gene in bloodstream-form T. brucei
Genetic manipulations were next carried out to validate GDPMan PP in T. brucei as a drug target. Southern blot analysis of T. brucei gDNA showed that GDP-Man PP is present as a single-copy gene per haploid genome (Supplementary Figure S5A at http://www.BiochemJ.org/bj/425/bj4250603add.htm) and it is expressed both in the bloodstream and procyclic life-cycle stages (Supplementary Figure S5B) .
As the 'wild-type' cell line used here constitutively expresses the T7 RNA polymerase and the tetracycline repressor protein, it was decided to introduce the Ti (tetracycline inducible) RNAi p2T7 vector containing the C-terminal domain of TbGDPMan PP. After drug selection with hygromycin, several clones were obtained, and the genotype of two were confirmed by Southern blot analysis ( Figure 4A , compare lane 1 with lanes 2 and 3).
To establish whether GDP-Man PP is an essential gene, RNAi cells at 5×10 4 cells/ml were grown in the absence or presence of tetracycline. Cells were counted each day and split when the density was between 2×10 6 and 3×10 6 (normally every second day). In the absence of tetracycline, cells showed normal growth rates and morphology ( Figure 4C ) when compared with wildtype cells ( Figure 4B ). However, in the presence of tetracycline (1 μg/ml, added daily) the RNAi cells grew normally for the first day, after which the cells either died or failed to divide ( Figure  4D ); these cells were swollen with multi-flagella (no specific cell-cycle arrest), until the number of live cells fell below the limits of detection by light microscopy. However, from approx. day 5-6, some live cells were visible by light microscopy, and after day 7 the cells resumed normal growth kinetics ( Figure  4D ). The presence of tetracycline with wild-type cells showed no detrimental growth or morphological affects, and did not affect the rate of protein synthesis (results not shown).
RT-PCR analysis ( Figure 4E) showed that the transcript level of GDP-Man PP in the RNAi cells induced for 24 h had decreased significantly: ∼ 20 % ( Figure 4E , lane 2) compared with the wild-type level ( Figure 4E, lane 1) . Whereas cells which had spontaneously resumed normal growth, despite the continued presence of tetracycline for 7 days, showed wild-type levels of transcript for the GDP-Man PP ( Figure 4E, lane 3) . This suggests 2 and 3 respectively) . The upper panel shows RT-PCR products using primers specific for TbGDP-Man PP; the lower panel shows a loading control using inositol-3-phosphate synthetase (TbINO1) primers as detailed in the Experimental section.
that these cells were revertants, able to break the tetracycline control, a phenomena which has been described previously for other essential genes in T. brucei [36, 44, 46] . Collectively these results clearly show that GDP-Man PP is an essential gene for the viability of the bloodstream-form T. brucei.
Biochemical phenotyping of the GDP-Man PP RNAi cells
GDP-Man levels from wild-type and GDP-Man PP RNAi cells
The direct effect of the RNAi knockdown on GDP-Man levels in the cells was assessed using ESI-MS/MS in conjuction with MRM. The intracellular concentrations of GTP, GDP-Hex and GDP-deoxy-Hex in wild-type and RNAi cells in the absence and presence of tetracycline were determined (Supplementary  Table S1 at http://www.BiochemJ.org/bj/425/bj4250603add. htm). GDP-Hex and GDP-deoxy-Hex concentrations of ∼ 15 μM and ∼ 0.5 μM respectively, in both wild-type and RNAi cells in the absence of tetracycline are similar to that previously observed for bloodstream T. brucei [35] , in which the authors also show that the only GDP-Hex and GDP-deoxy-Hex present in bloodstream T. brucei were GDP-Man and GDP-fucose respectively.
After 24 h of tetracycline induction of the RNAi cells, both GDP-Man and GDP-fucose levels decrease significantly, to ∼ 40 % and to ∼ 20 % of wild-type levels respectively (Supplementary Table S2 at http://www.BiochemJ.org/bj/ 425/bj4250603add.htm). The reduction in GDP-fucose is unsurprising as this is derived from GDP-Man via the concerted actions of the GDP-Man dehydratase (E.C. 4.2.1.47) and the GDPfucose synthase (E.C. 1.1.1.271).
As de novo synthesis of GDP-fucose has been shown to be essential in T. brucei, the subsequent death of the tetracyclineinduced GDP-Man PP RNAi cell line may be due to the absence of fucosylation of an as yet unknown acceptor(s) [13] .
Despite the decrease in the GDP-sugars, the intracellular concentration of GTP remains unchanged at ∼ 72 μM. This is probably unsurprising given the number, and importance, of other GTP-utilizing enzymes, including the GTPases, i.e. Rab/Ras proteins, involved in intracellular trafficking [37] . Thus the marginal increase due to GDP-Man PP not utilizing GTP is probably insignificant, and/or GTP levels may be very tightly regulated to ensure that levels do not vary significantly.
Neither the transcript levels nor the enzyme activity of the downstream Dol-P-Man synthase were affected upon RNAi induction of GDP-Man PP (results not shown).
Characterization of sVSG from wild-type and RNAi GDP-Man PP-induced cells
As VSG accounts for 10 % of total protein synthesis and as such is the cells' largest acceptor of GPI anchors and N-glycosylation, both of which are heavily dependent upon mannose activation directly or indirectly from GDP-Man, the consequence of lower amounts (∼ 20 %) of GDP-Man induced by RNAi were assessed by investigating the maturation (glycosylation) of VSG. sVSG was obtained by GPI-specific phospholipase C cleavage of the GPI-anchor of VSG [38] and purified from wild-type and GDPMan PP RNAi cells in the presence of tetracycline for 24 h.
Analysis by SDS/PAGE and Coomassie Blue staining showed wild-type sVSG as an expected single band (apparent molecular mass ∼ 54 kDa) ( Figure 5A, lane 1) , whereas sVSG prepared from the GDP-Man PP RNAi-induced cells appeared as a doublet, the wild-type sVSG band and an additional lower sVSG band with an apparent molecular mass ∼ 52 kDa ( Figure 5A, lane 2) .
[ 35 S]sVSG was isolated and purified from wild-type and RNAi-induced cells that were labelled with [
35 S]methionine. Proteins were separated by SDS/PAGE and 35 S-labelled proteins were detected by autoradiography. The incorporation of [
35 S]methionine into the newly synthesized sVSG shows a clear difference in migration between the two preparations, with the RNAi-induced-derived sVSG with an apparent lower molecular mass. Despite the molecular mass difference, the amount of incorporation is equal ( Figure 5B, compare lanes 1 and 2) , showing that at the time of labelling (24 h post-induction), the RNAi-induced cells are still fully viable and metabolically active. It should be noted that at later time points (32 and 36 h) the cells were not viable and thus 24 h induction was chosen at which to undertake all biochemical phenotyping. The observed changes in the sVSG were investigated using a variety of techniques to ascertain whether the molecular mass shift was due to differences in post-translational modifications, i.e. glycosylation, or in the protein. Both bands of the sVSG obtained from GDP-Man PP RNAi cells, were identified as VSG221 Figure S6, lane 6) . This is as expected [25] as the Endo H removes the high-mannose N-glycan at Asn 428 , the Asn 263 remains untouched, whereas the PNGase F digest removes both N-glycosylation modifications resulting in a further shift compared with that with Endo H. The Endo H and PNGase F digest of the sVSG obtained from the RNAi cells showed similar shifts in molecular mass (Supplementary Figure  S6, lanes 1-3) . The PNGase-F-treated fully de-glycosylated sVSG coincided with that of the wild-type sVSG treated, suggesting that any molecular-mass differences are a result of differences in Nglycosylation, despite the modified sVSG still having an Endo-Hsensitive and an Endo-H-resistant N-glycosylation site, like that of wild-type sVSG 221.
GPI biosynthesis in wild-type and RNAi-induced GDP-Man PP cells
The affect on GPI biosynthesis was also investigated by an in vivo [ 3 H]mannose labelling of the glycolipids. The only [ 3 H]mannose glycolipids observed in wild-type cells were as expected for mature GPI intermediates glycolipids A and C ( Figure 5C , lane 3) [22] . Glycolipids A and C were also observed at similar amounts in the RNAi cells in the absence of tetracycline ( Figure 5C , lane 2). After 24 h induction, the levels of both glycolipids A and C were significantly reduced (∼ 40 %; Figure 5C , lane 1); however, glycolipid A, the mature precursor for GPI attachment to VSG, can still be seen. This suggests that at this time point (24 h) there is still sufficient GDP-Man to make sufficient Dol-P-Man to be used by the GPI biosynthetic pathway to make sufficient mature GPI anchor for attachment to newly synthesized VSG. However, beyond this time point it is highly conceivable that this would not be the case and insufficient GPI biosynthesis for VSG maturation, subsequently leading to cell death as previously hypothesized in the genetic and chemical validation of GPI biosynthesis in bloodstream T. brucei [20] [21] [22] .
Characterization of glycopeptides from pronase digests of sVSG from wild-type and RNAi-induced GDP-Man PP cells
In order to investigate the N-glycosylation modifications further, ESI-MS spectra of the intact sVSG glycoprotein were collected as described in the Experimental section.
The spectrum of wild-type sVSG ( Figure 6A ) is similar to that described previously for the sVSG221 variant [25] . The observed various glycoforms are as a result of structural heterogeneity at the two N-glycosylation sites [24] and in the GPI anchor [23] , and are described in full in Supplementary Table S1 .
The sVSG spectrum of the RNAi-induced cells ( Figure 6B ) shows two distinct envelopes of sVSG glycoforms, consistent with the two sVSG bands seen by SDS/PAGE ( Figure 5A ). The lower-molecular-mass group of glycoforms has masses consistent with the C-terminal Asn 428 N-glycosylation site being unoccupied, with Asn 263 containing the basis of a complex Nglycosylation (Supplementary Table S1 ).
The higher-molecular-mass group of glycoforms, with both N-glycosylation sites occupied, have similar glycoforms to that of the wild-type sVSGs. However, the distribution is different, with variations being in the N-terminal N-glycosylation site (Supplementary Table S1 ).
To investigate these changes in the glycoforms of sVSG upon reduced GDP-Man levels, purified sVSG from of both wild-type and induced RNAi GDP-Man PP cells were digested with pronase. Glycopeptides were isolated as described in the Experimental section prior to analysis by ESI-MS/MS using collison-induced fragmentation of neutral loss of 81 m/z, a double-charged loss of a terminal hexose (Figure 7 ). There were no observed differences in the masses of the GPI-peptide fragment between wild-type and those previously characterized from sVSG variant 221 [25] . However, there were significant differences in the masses for the glycopeptides of the C-terminal (Asn 428 ) fragment, which contains the Man 9−8 GlcNAc 2 glycan between the wild-type and the RNAiinduced cells. The absence of lower mannosylated forms at this site suggest that the reduction in GDP-Man levels does not cause immature N-glycan precursors to be transferred to the nascent chain of the newly synthesized VSG protein. If this was the case the Man 5 GlcNAc 2 glycans may be seen at this position.
Instead, changes in the N-glycan attached to the N-terminal (Asn 263 ) glycosylation site were observed. In the wild-type sVSG the Man 3 GlcNAc 2 is predominant as previously described [25] . In the RNAi-induced cells this N-glycosylation site is occupied Table S1 (at http://www.BiochemJ.org/bj/425/bj4250603add.htm) shows the composition of all of the glycoforms observed both in (A) and (B). The glycan structures are represented by filled boxes for GlcNAc residues, filled circles for Man residues, empty circles for Gal residues and empty boxes for GlcN residues.
by a range of glycans including Man 3−5 GlcNAc 2 , with the Man 4 and Man 5 species being significantly more noticeable in the sVSG obtained from the RNAi-induced cells than the wild-type cells; this is mirrored by the increase in the intact sVSG glycoforms at 51022 and 51186 m/z (Figures 6A and 6B ).
There are also other changes in the predominant species at the Asn 263 glycosylation site which are modified further with lactosamine groups, as depicted in Figure 7 (B), and these are reflected in the intact sVSG glycoforms at 51058 and 51222 m/z ( Figure 6B ).
The glycans observed for the glycoforms of sVSG that have the unoccupied C-terminal glycosylation site in the RNAiinduced cells ( Figure 6B , 49-50 kDa), only have species with part of, or up to two, lactosamine repeats at the N-terminal (Asn 263 ) glycosylation site. In other words there is no evidence of Man 3−5 GlcNAc 2 species at this site once the high-mannosecontaining glycan at the C-terminal glycosylation site has been lost.
Collectively, these data suggest that a reduction in the amount of GDP-Man affects VSG N-glycosylation, such that they sacrifice N-glycosylation at Asn 428 while maintaining the N-glycosylation at Asn 263 , which only utilizes a Man 5 form which can be further processed in a site-specific manner, Man 9 GlcNAc 2 -PP-Dol for Asn 428 and Man 5 GlcNAc 2 -PP-Dol for Asn 263 of VSG221 and . Ser-GPI represents serine-ethanolaminephosphate-6Manα1-2Manα1-6Manα1-4GlcNα1-6-D-myo-inositol-1,2-cyclic phosphate and NETAG, NET and GNTNTT are single-letter amino acid sequences for the N-and C-terminal N-glycosylation sites, Asn 263 and Asn 428 respectively. The glycopeptide structures are represented by filled boxes for GlcNAc residues, filled circles for Man residues, empty circles for Gal residues and empty boxes for GlcN residues.
presumably other VSG variants, and may be other important glycoproteins for the parasite, i.e. p67 and transferrin receptor.
In summary, the results of the present study clearly demonstrated that the viability of the bloodstream form of T. brucei is dependent on mannose activation, i.e. formation of GDPMan. This dependence has been confirmed genetically by the perturbation of growth by a TbGDP-Man PP RNAi cell line, thus validating TbGDP-Man PP in bloodstream-form T. brucei as a potential therapeutic drug target.
Recombinant expression and purification of catalytically active TbGDP-Man PP protein has allowed kinetic characterization, demonstrating product feedback inhibition and paves the way for future high-throughput screening. Indeed a competitive inhibitor of this important biosynthetic step may only have to inhibit by ∼ 80 % to be lethal to the parasite, based upon the observed GDPMan and GTP levels in the cell.
We are now actively investigating other aspects of mannose metabolism in T. brucei and related diseases for other potential drug targets, and compounds that interfere with mannose activation in a parasite-specific manner. 3) were subjected to digests with either nothing/control (lanes 1 and 4), Endo H (lanes 2 and 5) or PNGase F (lanes 3 and 6). Molecular mass standards are indicated on the left-hand side.
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